Picture of Malin logo

MLC Malin News Story

0.000.00%
ie flag iconLast trade - 00:00
HealthcareAdventurousSmall CapMomentum Trap

REG - Malin Corp PLC - Holding(s) in Company





 




RNS Number : 9728G
Malin Corporation PLC
12 November 2018
 

 



Malin Corporation plc 

('Malin' or 'the Company')

 

Holding(s) in Company

 

Malin received notification on 9 November, 2018 from Aviva Investors Global Services Limited that as of 8 November, 2018 it holds an aggregate interest  in 2,706,986 ordinary shares of €0.001 each, which represents 5.93%* of the issued share capital of the Company. 

 

*This percentage shareholding is based on a shares in issue figure of 45,662,061 ordinary shares.

 

Contacts:

 

Malin

Jessica Bergin, Director of Investor Relations and External Reporting

Tel: +353 1 901 5700

 

Davy Corporate Finance (ESM Adviser)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

 

Powerscourt (Ireland PR)

Consilium Strategic Communications (UK PR)

Eavan Gannon

Mary-Jane Elliott / Jonathan Birt

Tel: +353 353 87 236 5973

Tel: +44 (0)20 3709 5700

info@powerscourt-group.com

malin@consilium-comms.com

 

About Malin Corporation Plc

Malin (ISE:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on Euronext Dublin. For more information visit www.malinplc.com 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLVKLFBVFFEFBF

Recent news on Malin

See all news